Cargando…

Managing Encephalopathy in the Outpatient Setting

In cirrhosis of liver, hepatic encephalopathy (HE) has an important impact on health-related quality of life. It is important to define whether HE is episodic, recurrent, or persistent; types A, B, or C; overt HE or covert HE; and spontaneous or precipitated. The overt HE is clinically evident and n...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Tarana, Rathi, Sahaj, K Dhiman, Radha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663774/
https://www.ncbi.nlm.nih.gov/pubmed/29201772
http://dx.doi.org/10.5005/jp-journals-10018-1211
_version_ 1783274877769220096
author Gupta, Tarana
Rathi, Sahaj
K Dhiman, Radha
author_facet Gupta, Tarana
Rathi, Sahaj
K Dhiman, Radha
author_sort Gupta, Tarana
collection PubMed
description In cirrhosis of liver, hepatic encephalopathy (HE) has an important impact on health-related quality of life. It is important to define whether HE is episodic, recurrent, or persistent; types A, B, or C; overt HE or covert HE; and spontaneous or precipitated. The overt HE is clinically evident and needs hospitalization. Nonabsorbable disaccharides, rifaximin, and probiotics are proven to be useful in the treatment of overt HE. Covert HE includes both minimal HE and grade I HE. It is not apparent on routine clinical examination. Presence of poor work productivity, increased accidental injuries on complex machinery and driving, etc., raise the suspicion of cognitive dysfunction. Specialized neurocognitive testing like psychometric HE, computerized tests like critical flicker frequency tests, inhibitory control tests, Stroop encephalopathy tests, and electroencephalography are needed to diagnose overt HE. Various studies have shown lactulose and rifaximin to be useful in overt HE. However, presence of persistent and recurrent HE in cirrhosis is an indication for liver transplant. Lactulose is effective both in improving reversal of minimal HE and in reducing the risk of development of overt HE. How to cite this article: Gupta T, Rathi S, Dhiman RK. Managing Encephalopathy in the Outpatient Setting. Euroasian J Hepato-Gastroenterol 2017;7(1):48-54.
format Online
Article
Text
id pubmed-5663774
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Jaypee Brothers Medical Publishers
record_format MEDLINE/PubMed
spelling pubmed-56637742017-11-30 Managing Encephalopathy in the Outpatient Setting Gupta, Tarana Rathi, Sahaj K Dhiman, Radha Euroasian J Hepatogastroenterol Mini Review In cirrhosis of liver, hepatic encephalopathy (HE) has an important impact on health-related quality of life. It is important to define whether HE is episodic, recurrent, or persistent; types A, B, or C; overt HE or covert HE; and spontaneous or precipitated. The overt HE is clinically evident and needs hospitalization. Nonabsorbable disaccharides, rifaximin, and probiotics are proven to be useful in the treatment of overt HE. Covert HE includes both minimal HE and grade I HE. It is not apparent on routine clinical examination. Presence of poor work productivity, increased accidental injuries on complex machinery and driving, etc., raise the suspicion of cognitive dysfunction. Specialized neurocognitive testing like psychometric HE, computerized tests like critical flicker frequency tests, inhibitory control tests, Stroop encephalopathy tests, and electroencephalography are needed to diagnose overt HE. Various studies have shown lactulose and rifaximin to be useful in overt HE. However, presence of persistent and recurrent HE in cirrhosis is an indication for liver transplant. Lactulose is effective both in improving reversal of minimal HE and in reducing the risk of development of overt HE. How to cite this article: Gupta T, Rathi S, Dhiman RK. Managing Encephalopathy in the Outpatient Setting. Euroasian J Hepato-Gastroenterol 2017;7(1):48-54. Jaypee Brothers Medical Publishers 2017 2017-05-05 /pmc/articles/PMC5663774/ /pubmed/29201772 http://dx.doi.org/10.5005/jp-journals-10018-1211 Text en Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd. This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
spellingShingle Mini Review
Gupta, Tarana
Rathi, Sahaj
K Dhiman, Radha
Managing Encephalopathy in the Outpatient Setting
title Managing Encephalopathy in the Outpatient Setting
title_full Managing Encephalopathy in the Outpatient Setting
title_fullStr Managing Encephalopathy in the Outpatient Setting
title_full_unstemmed Managing Encephalopathy in the Outpatient Setting
title_short Managing Encephalopathy in the Outpatient Setting
title_sort managing encephalopathy in the outpatient setting
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663774/
https://www.ncbi.nlm.nih.gov/pubmed/29201772
http://dx.doi.org/10.5005/jp-journals-10018-1211
work_keys_str_mv AT guptatarana managingencephalopathyintheoutpatientsetting
AT rathisahaj managingencephalopathyintheoutpatientsetting
AT kdhimanradha managingencephalopathyintheoutpatientsetting